Curis Goes Above 'Erivedge' With $30M, Licensing Deal
Pulling down a $30 million loan against Erivedge royalties and spending $9.5 million to license a Phase II-ready apoptosis promoter from Genentech Inc. its partner for the skin cancer product gives Curis Inc. more financial runway, as well as worldwide rights to another promising oncology candidate.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter